Abstract
Biosimilar trastuzumab (trastuzumab-qyyp) was the fourth trastuzumab biosimilar in Europe in 2018. The objectives of this study were to understand the utilization of biosimilar trastuzumab and its benefits and risks in a real-world setting. Materials and methods: In this observational study, patients in the Netherlands and Norway treated with biosimilar trastuzumab for early stage (stage 0-3) HER2+ breast cancer were recruited (February 2020-July 2021). Data recorded were biosimilar trastuzumab treatment patterns, patient demographics, clinical characteristics, tolerability, and healthcare resource utilization (HCRU).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
